biological source
mouse
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
11, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (415M-14)
vial of 0.5 mL concentrate (415M-15)
bottle of 1.0 mL predilute (415M-17)
vial of 1.0 mL concentrate (415M-16)
bottle of 7.0 mL predilute (415M-18)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
isotype
IgG1
control
breast carcinoma, prostate adenocarcinoma, tonsil
shipped in
wet ice
storage temp.
2-8°C
visualization
nuclear
Gene Information
human ... EZH2(2146)
Analysis Note
![]() IVD | ![]() IVD | ![]() IVD | ![]() RUO |
General description
Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). It generates a methylation epigenetic mark at lysine 27 residue of histone H3 (H3K27me3) in order to silence gene expression. EZH2 target genes are involved in a variety of biological processes such as stem cell pluripotency, cell proliferation, and oncogenic transformation. EZH2 is frequently overexpressed in many cancer types. Hyperactivation of EZH2, either by overexpression or mutations, is found in a variety of malignancies including prostate, breast, uterine, gastric, and renal cell cancers in addition to melanoma. EZH2 overexpression has been reported in non-small cell lung cancers and lymphoma.The EZH2 protein is rarely detected in normal breast duct epithelium and in normal and hyperplastic lymph node. EZH2 is usually expressed in follicular centers, but not in mantle zones, follicular and interfollicular T cells, plasma cells or NK/T cells. However, its expression can be seen in most B-cell and T-cell lymphomas, although only in 20% (1/5) of small lymphocytic lymphoma and 14% (1/7) of plasma cell myeloma. Plasmacytoma, lymphoplasmacytic lymphoma, and MALT lymphoma have not been shown to express this protein. Recent studies also have demonstrated EZH2 is aberrantly over-expressed in pediatric rhabdomyosarcoma, independent of the histological subtypes. In summary, EZH2 correlates with tumor proliferation and may be used in an antibody panel to differentiate proliferative/aggressive lymphoma variants from indolent ones and normal resting cell populations
Other Notes
EZH2 Positive Control Slides, Product No. 415S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品?
试试我们的产品选型工具.
法规信息
监管及禁止进口产品
此项目有
Jin-zhi Tan et al.
Acta pharmacologica Sinica, 35(2), 161-174 (2013-12-24)
EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. Overexpression of EZH2 has been found in a wide range of cancers, including those
Lamia Abd Al Kader et al.
Virchows Archiv : an international journal of pathology, 463(5), 697-711 (2013-08-21)
Polycomb group (PcG) proteins are important for the regulation of hematopoiesis by regulating chromatin compaction and silencing genes related to differentiation and cell cycle. Overexpression of enhancer of zeste homologue 2 (Ezh2) and Bmi-1/PCGF4 has been implicated in solid organ
Sooryanarayana Varambally et al.
Nature, 419(6907), 624-629 (2002-10-11)
Prostate cancer is a leading cause of cancer-related death in males and is second only to lung cancer. Although effective surgical and radiation treatments exist for clinically localized prostate cancer, metastatic prostate cancer remains essentially incurable. Here we show, through
Roberta Ciarapica et al.
BMC medicine, 9, 63-63 (2011-05-26)
Soft tissue sarcomas of childhood are a group of heterogeneous tumors thought to be derived from mesenchymal stem cells. Surgical resection is effective only in about 50% of cases and resistance to conventional chemotherapy is often responsible for treatment failure.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持


